PRINCETON, N.J.— 2021年8月24日. Certara, the global leader in biosimulation, today announced the appointments of Terri Madison, Ph.D. as Senior Vice President and General Manager of Evidence and Access, Heather Valentine as Senior Vice President of Software Sales and Marketing, and Ron DiSantis as Senior Vice President of Corporate Development. These new appointments will further advance the Company’s end-to-end platform and global expansion plans.
Dr. Madison brings more than 30 years of experience in data management, biostatistics, epidemiology, safety surveillance, and risk management. Reporting to Justin Edge, President of Regulatory and Access, she will lead the build-out of Certara’s advanced analytics, data and technology platforms to support real world evidence and access solutions. Dr. Madison previously served as Vice President, Scientific Affairs and Head, Real World Evidence Strategy and Analytics at ICON plc. She earned her Ph.D. and a master’s in public health in epidemiology from the University of Michigan.
“It is my sincere pleasure to join Certara’s evidence and access team,” said Dr. Madison. “With the growth of complex targeted therapies and increasing evidentiary requirements, there is an exciting opportunity to inform access and drug development decisions with more robust evidence and analytics.”
Heather Valentine as Senior Vice President of Sales and Marketing will report to Leif Pedersen, President of Software. She has more than two decades of experience building high performing enterprise software global sales teams in the life sciences industry. Ms. Valentine has an extensive leadership record, which has resulted in double digit revenue growth at every organization she has served. Previously, Ms. Valentine was Senior Vice President of Global Sales, Services and Enablement at Dassault Systèmes BIOVIA, where her responsibilities included revenue growth, customer success, professional services and value delivery. Ms. Valentine earned her bachelor’s in public administration from Grand Valley State University in Michigan.
“I am grateful to be able to offer my vast experience to an innovative and transformative company like Certara,” said Ms. Valentine. “I look forward to collaborating with such a strong team to help increase research productivity and improve patient outcomes by providing access to Certara’s leading clinical, regulatory, and market access software around the globe.”
Ron DiSantis joins Certara as Senior Vice President, Corporate Development. Prior to joining Certara, Mr. DiSantis served as Vice President, Head of Americas, Corporate Development at IQVIA where he was responsible for mergers and acquisitions and other inorganic growth strategies. Mr. DiSantis brings more than 15 years of experience managing strategic growth programs as proven by a track record of identifying and executing on acquisitions and other investments. In his role at Certara, he will report to CEO William F. Feehery and oversee initiatives to strengthen Certara’s footprint globally. Mr. DiSantis holds a master’s in business administration from the Fox School of Business at Temple University in Philadelphia.
“I am excited to join the Certara team and oversee its corporate development program,” said Mr. DiSantis. “I look forward to helping the Company execute on its growth strategy and expand its impact on drug discovery and development globally.”
Certara（サターラ）について
サターラは、バイオシミュレーションソフトウェアと技術を用いて、従来の創薬・開発を変革し、医薬品をよりスピーディーに患者さんに届けることをミッションとしています。バイオ医薬品企業1,650社以上、主要学術機関、主要な規制当局がサターラのソフトウェアやコンサルティングサービスを利用しております。弊社のお客様は61か国以上に広がっております。
投資家の皆様：
David Deuchler
Gilmartin Group
ir@certara.com
報道機関の皆様：
赤津 笑美
emi.akatsu@certara.com
ariane.lovell@finnpartners.com
